Rezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science

About this update from Rezolute, Inc.

[{"type":"text","content":"REDWOOD CITY, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OCTQB:RZLT), announced that the company’s abstract accepted to the virtual Association for Research in Vision and Ophthalmology (ARVO) 2020 meeting, titled “Nonclinical safety and pharmacology of RZ402, a plasma kallikrein inhibitor, for the treatment of diabetic macular edema as a daily oral therapy,” was published in the peer-reviewed journal Investigative Ophthalmology & Visual Science.\n “In people with diabetes, localized activation of the kallikrein/kinin pathway in the eye may increase vascular permeability and fluid leakage. That leakage may lead to swelling, or edema, of the macula, which in turn may cause vision loss or even total blindness,” said Sankaram Mantripragada, Ph.D., Rezolute’s chief scientific officer. “Small molecule RZ402 inhibits the action of that kallikrein pathway, potentially offering the means to clinical treatment objectives including edema reduction and improved visual acuity in people with DME. We have found in relevant animal models that RZ402 demonstrates an excellent safety profile in both single- and repeat-dosing settings at a range of doses. Importantly, exposure-dependent plasma levels of the drug are consistent with once-daily oral dosing, an encouraging signal as we plan clinical trials.” Highlighted results of RZ402 single and repeat oral dosing studies in rats and cynomolgus monkeys include the following: RZ402 demonstrated an excellent ADME (absorption, distribution, metabolism and excretion) profile, with moderate renal clearancePlasma levels of RZ402 remained above EC50 for 24 hours after dosing, consistent with a daily oral dose regimenNo adverse effects were seen in rat models after repeat-dose administration at over 500-fold excess dosing (up to 1,000 mg/kg) for 7 daysNo adverse effects were seen in respiratory or central nervous system safety pharmacology studies (up to 1,000 mg/kg) in rats or in cardiovascular safety studies (up to 400 mg/kg) in monkeysDose-proportional exposure up to 800 mg/kg in monkeys “As a prevalent complication of diabetes, DME threatens vision in 1 to 2 million patients in the United States alone,” said Nevan Elam, CEO of Rezolute. “Up to half of those patients respond sub-optimally to standard-of-care anti-VEGF therapy, which requires direct injections ...

More updates from Rezolute, Inc.